KR102867725B1 - 골수형성이상 증후군의 치료 방법 - Google Patents

골수형성이상 증후군의 치료 방법

Info

Publication number
KR102867725B1
KR102867725B1 KR1020207003450A KR20207003450A KR102867725B1 KR 102867725 B1 KR102867725 B1 KR 102867725B1 KR 1020207003450 A KR1020207003450 A KR 1020207003450A KR 20207003450 A KR20207003450 A KR 20207003450A KR 102867725 B1 KR102867725 B1 KR 102867725B1
Authority
KR
South Korea
Prior art keywords
mds
subject
imetelstat
weeks
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003450A
Other languages
English (en)
Korean (ko)
Other versions
KR20200033269A (ko
Inventor
알렉산드라 리조
재클린 시릴로 부솔라리
Original Assignee
제론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102867725(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제론 코포레이션 filed Critical 제론 코포레이션
Priority to KR1020257032602A priority Critical patent/KR20250151565A/ko
Publication of KR20200033269A publication Critical patent/KR20200033269A/ko
Application granted granted Critical
Publication of KR102867725B1 publication Critical patent/KR102867725B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207003450A 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법 Active KR102867725B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257032602A KR20250151565A (ko) 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US62/538,315 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US62/595,329 2017-12-06
US201862685542P 2018-06-15 2018-06-15
US62/685,542 2018-06-15
PCT/US2018/044225 WO2019023667A1 (en) 2017-07-28 2018-07-27 METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257032602A Division KR20250151565A (ko) 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법

Publications (2)

Publication Number Publication Date
KR20200033269A KR20200033269A (ko) 2020-03-27
KR102867725B1 true KR102867725B1 (ko) 2025-10-13

Family

ID=63209674

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207003450A Active KR102867725B1 (ko) 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법
KR1020257032602A Pending KR20250151565A (ko) 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257032602A Pending KR20250151565A (ko) 2017-07-28 2018-07-27 골수형성이상 증후군의 치료 방법

Country Status (18)

Country Link
US (2) US12171778B2 (https=)
EP (1) EP3658156B1 (https=)
JP (4) JP7316261B2 (https=)
KR (2) KR102867725B1 (https=)
CN (2) CN121243203A (https=)
AU (2) AU2018307983B2 (https=)
BR (1) BR112020001749A2 (https=)
CA (1) CA3069010A1 (https=)
CL (2) CL2020000196A1 (https=)
IL (2) IL324714A (https=)
MA (1) MA49688A (https=)
MX (1) MX2025005894A (https=)
NZ (2) NZ802272A (https=)
SG (1) SG11201913984RA (https=)
TW (2) TWI879717B (https=)
UA (1) UA127701C2 (https=)
WO (1) WO2019023667A1 (https=)
ZA (1) ZA202000070B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
KR20250074692A (ko) * 2018-11-29 2025-05-27 제론 코포레이션 골수이형성 증후군을 치료하는 방법
IL299205A (en) 2020-07-17 2023-02-01 Geron Corp Subcutaneous telomerase inhibitor preparations and methods of using them
CN116887844A (zh) * 2021-01-18 2023-10-13 活跃生物技术有限公司 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069758A1 (en) * 2013-11-06 2015-05-14 Ayalew Tefferi Methods and materials for treating hematological malignancies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2440322C (en) 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
TW200730485A (en) 2005-07-29 2007-08-16 Kalypsys Inc Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
LT2898887T (lt) 2006-10-30 2018-11-12 Geron Corporation Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
EP2134364B1 (en) 2007-03-09 2013-02-13 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP3029154B1 (en) 2008-10-17 2017-10-04 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
WO2011017096A2 (en) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
JP5937520B2 (ja) 2010-02-12 2016-06-22 イプソゲン 骨髄性腫瘍の新規診断マーカーとしてのａｓｘｌ１
AU2012249531B2 (en) 2011-04-29 2017-06-29 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
JP6359028B2 (ja) 2012-11-30 2018-07-18 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069758A1 (en) * 2013-11-06 2015-05-14 Ayalew Tefferi Methods and materials for treating hematological malignancies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Tefferi 외, "Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis", Blood Cancer Journal, 제6권, 논문번호 e405 (2016. 3. 11. 온라인 공개)*
Antonio Almeida 외, "Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)", Leukemia Research, 제52권, 제50-57면 (2016. 11. 13. 온라인 공개)*

Also Published As

Publication number Publication date
CL2020000196A1 (es) 2020-11-20
JP2024015000A (ja) 2024-02-01
CA3069010A1 (en) 2019-01-31
EP3658156A1 (en) 2020-06-03
UA127701C2 (uk) 2023-12-06
KR20250151565A (ko) 2025-10-21
CN110944646A (zh) 2020-03-31
JP2020528915A (ja) 2020-10-01
AU2018307983B2 (en) 2024-07-18
BR112020001749A2 (pt) 2020-07-21
US20190030064A1 (en) 2019-01-31
AU2024219941A1 (en) 2024-10-10
SG11201913984RA (en) 2020-02-27
EP3658156B1 (en) 2026-03-25
JP7654615B2 (ja) 2025-04-01
CL2021001096A1 (es) 2021-11-12
NZ802272A (en) 2026-03-27
IL272163A (en) 2020-03-31
WO2019023667A1 (en) 2019-01-31
NZ802277A (en) 2026-03-27
IL272163B1 (en) 2025-12-01
KR20200033269A (ko) 2020-03-27
JP2023009229A (ja) 2023-01-19
TW201919705A (zh) 2019-06-01
MX2025005894A (es) 2025-06-02
JP2025013669A (ja) 2025-01-24
JP7316261B2 (ja) 2023-07-27
CN121243203A (zh) 2026-01-02
JP7654761B2 (ja) 2025-04-01
MA49688A (fr) 2020-06-03
TW202432146A (zh) 2024-08-16
TWI879717B (zh) 2025-04-11
US20260115223A1 (en) 2026-04-30
AU2018307983A1 (en) 2020-02-13
ZA202000070B (en) 2025-09-25
US12171778B2 (en) 2024-12-24
TWI906757B (zh) 2025-12-01
NZ760873A (en) 2024-03-22
IL324714A (en) 2026-01-01

Similar Documents

Publication Publication Date Title
KR102867725B1 (ko) 골수형성이상 증후군의 치료 방법
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
EA050072B1 (ru) Способы лечения миелодиспластического синдрома
EA043524B1 (ru) Способы лечения миелодиспластического синдрома
EA045910B1 (ru) Способы лечения миелодиспластического синдрома
HK40027129A (en) Methods of treating myelodysplastic syndrome
EA052010B1 (ru) Способы лечения миелодиспластического синдрома
HK40063245A (en) Methods of treating myelodysplastic syndrome

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 162